<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="9271"><DrugName>pralnacasan</DrugName><DrugNamesKey><Name id="42773468">ICE inhibitor, Vertex/Aventis</Name><Name id="42759842">pralnacasan</Name></DrugNamesKey><DrugSynonyms><Name><Value>pralnacasan</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>VX-740</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>3480</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VX-70</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RU-36384</Value><Types><Type>Metabolite</Type></Types></Name><Name><Value>VE-18858</Value><Types><Type>Metabolite</Type></Types></Name><Name><Value>HMR-3480A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VRT-18858</Value><Types><Type>Metabolite</Type></Types></Name><Name><Value>ICE inhibitor, Vertex/Aventis</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>ICE inhibitor, Vertex/sanofi-aventis</Value></Name><Name><Value>HMR-3480</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>192755-52-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20739">Vertex Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="1009547">Sanofi SA</Company><Company id="20739">Vertex Pharmaceuticals Inc</Company><Company id="25218">Aventis Pharma AG</Company><Company id="25224">Hoechst Marion Roussel Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="9271" type="Drug"><TargetEntity id="252678" type="siDrug">Pralnacasan</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="20739" type="Company"><TargetEntity id="4295908317" type="organizationId">Vertex Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="25218" type="Company"><TargetEntity id="4296758779" type="organizationId">Aventis Pharma AG</TargetEntity></SourceEntity><SourceEntity id="25224" type="Company"><TargetEntity id="4295910625" type="organizationId">Aventis Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1069" type="ciIndication"><TargetEntity id="10062194" type="MEDDRA"></TargetEntity><TargetEntity id="D009362" type="MeSH"></TargetEntity><TargetEntity id="-1423187778" type="omicsDisease"></TargetEntity><TargetEntity id="618" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="114" type="ciIndication"><TargetEntity id="10040047" type="MEDDRA"></TargetEntity><TargetEntity id="D018805" type="MeSH"></TargetEntity><TargetEntity id="-200243460" type="omicsDisease"></TargetEntity><TargetEntity id="953" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="245" type="ciIndication"><TargetEntity id="10031161" type="MEDDRA"></TargetEntity><TargetEntity id="D010003" type="MeSH"></TargetEntity><TargetEntity id="-478836143" type="omicsDisease"></TargetEntity><TargetEntity id="747" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="97" type="ciIndication"><TargetEntity id="10012601" type="MEDDRA"></TargetEntity><TargetEntity id="D003920" type="MeSH"></TargetEntity><TargetEntity id="-203480060" type="omicsDisease"></TargetEntity><TargetEntity id="506" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="791" type="Action"><TargetEntity id="438" type="Mechanism">Caspase 1 (IL-1beta Converting Enzyme) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="PTGT-00971" type="ciTarget"><TargetEntity id="11303314518343" type="siTarget">Caspase-1</TargetEntity><TargetEntity id="370" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1069">Metastasis</Indication><Indication id="114">Sepsis</Indication><Indication id="14">Alzheimers disease</Indication><Indication id="188">Inflammatory disease</Indication><Indication id="245">Osteoarthritis</Indication><Indication id="281">Psoriasis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="97">Diabetes mellitus</Indication></IndicationsSecondary><ActionsPrimary><Action id="791">ICE inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="15184">Systemic antipsoriatic product</Action><Action id="1545">Anticancer</Action><Action id="2953">Anti-inflammatory</Action><Action id="695">Metastasis inhibitor</Action></ActionsSecondary><Technologies><Technology id="1263">Immuno-oncology</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>A10</Code><Name>DRUGS USED IN DIABETES</Name></Ephmra><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-28T08:43:37.000Z</LastModificationDate><ChangeDateLast>2017-11-30T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="20739" linkType="Company"&gt;Vertex&lt;/ulink&gt;  was developing pralnacasan (3480, HMR-3480, VX-740), an interleukin 1-beta converting enzyme (ICE) inhibitor prodrug of VRT-18858 (RU-36384), for the potential treatment of inflammatory diseases, particularly osteoarthritis  and rheumatoid arthritis [&lt;ulink linkID="170247" linkType="reference"&gt;170247&lt;/ulink&gt;], [&lt;ulink linkID="188293" linkType="reference"&gt;188293&lt;/ulink&gt;], [&lt;ulink linkID="453094" linkType="reference"&gt;453094&lt;/ulink&gt;], [&lt;ulink linkID="563401" linkType="Reference"&gt;563401&lt;/ulink&gt;]. By September 1999, pralnacasan was in phase  II rheumatoid arthritis trials  [&lt;ulink linkID="339915" linkType="Reference"&gt;339915&lt;/ulink&gt;]; however, by November 2003, these trials had been halted due to safety concerns until non-clinical toxicity testing could be completed [&lt;ulink linkID="512452" linkType="Reference"&gt;512452&lt;/ulink&gt;]. By January 2004, a phase II trials for osteoarthritis (OA) had also been completed  [&lt;ulink linkID="633246" linkType="Reference"&gt;633246&lt;/ulink&gt;]. Both these indications were listed as in ongoing development by Vertex in November 2005, following termination of development by Vertex's former collaborator &lt;ulink linkID="1009547" linkType="Company"&gt;sanofi-aventis&lt;/ulink&gt; in the first half of 2005, although clinical development was still suspended at that time while the findings of the toxicology study were being evaluated [&lt;ulink linkID="633246" linkType="Reference"&gt;633246&lt;/ulink&gt;]. In March 2006, data from non-clinical toxicity tests were forecast to be disclosed during that year; at that time, the company was considering seeking to outlicense the program [&lt;ulink linkID="670785" linkType="Reference"&gt;670785&lt;/ulink&gt;].       &lt;/para&gt;&lt;para&gt;Pralnacasan was previously being developed for potential treatment of psoriasis; by February 2004, phase I/II trials in psoriasis patients had begun [&lt;ulink linkID="523891" linkType="Reference"&gt;523891&lt;/ulink&gt;], [&lt;ulink linkID="524359" linkType="Reference"&gt;524359&lt;/ulink&gt;]; however, no development has been reported for that indication since that time. Pralnacasan was  also previously being investigated for Alzheimer's disease, sepsis, metastasis and diabetes; however, by 2001, development for these indications had been discontinued [&lt;ulink linkID="401955" linkType="reference"&gt;401955&lt;/ulink&gt;], [&lt;ulink linkID="427421" linkType="reference"&gt;427421&lt;/ulink&gt;]. &lt;ulink&gt;Sanofi-aventis&lt;/ulink&gt; (formerly Aventis and previously  &lt;ulink linkID="26086" linkType="Company"&gt;Hoechst Marion Roussel&lt;/ulink&gt;; HMR) had been codeveloping the drug with Vertex; however, pralnacasan was not listed on sanofi-aventis' March 2005 pipeline [&lt;ulink linkID="587512" linkType="Reference"&gt;587512&lt;/ulink&gt;]. By April 2005, it had informed Vertex that it was terminating the agreement and returning full rights to the drug to Vertex [&lt;ulink linkID="597722" linkType="Reference"&gt;597722&lt;/ulink&gt;], [&lt;ulink linkID="620356" linkType="Reference"&gt;620356&lt;/ulink&gt;].  In August 2005, sanofi-aventis confirmed that development had been terminated [&lt;ulink linkID="620356" linkType="Reference"&gt;620356&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Vertex was also  developing second-generation ICE inhibitors  (&lt;ulink linkID="31241" linkType="Drug"&gt;VX-765&lt;/ulink&gt;; qv) for various conditions that include psoriasis.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;RHEUMATOID ARTHRITIS&lt;/subtitle&gt;In November 2002, Aventis was expected to initiate a phase IIb trials designed to explore higher doses of pralnacasan and to evaluate the safety and efficacy of the compound in RA in the second quarter of 2003 [&lt;ulink linkID="470529" linkType="reference"&gt;470529&lt;/ulink&gt;], [&lt;ulink linkID="487210" linkType="reference"&gt;487210&lt;/ulink&gt;]. In May 2003, Vertex announced that Aventis was on target to initiate the trials in the second quarter of that year [&lt;ulink linkID="488216" linkType="reference"&gt;488216&lt;/ulink&gt;],  [&lt;ulink linkID="495755" linkType="reference"&gt;495755&lt;/ulink&gt;]. In July 2003, Aventis began enrollment in the US and Canada. The randomized, placebo-controlled, double-blind, multicenter trial would evaluate pralnacasan in patients with RA receiving stable methotrexate treatment. 400 patients were to be treated with pralnacasan or placebo for 12 weeks [&lt;ulink linkID="496567" linkType="reference"&gt;496567&lt;/ulink&gt;]. In September 2003, results from this trial were expected in late 2004 [&lt;ulink linkID="509199" linkType="reference"&gt;509199&lt;/ulink&gt;]. In November 2003, this trial was halted due to results from an animal toxicology study that showed liver abnormalities after exposure to high doses of the drug for 9 months. At this time, 330 patients had been enrolled and 50 patients had completed treatment, but no significant adverse events associated with liver toxicity were observed. The companies were to analyze toxicity data before making a decision regarding the future  development for this indication [&lt;ulink linkID="512452" linkType="reference"&gt;512452&lt;/ulink&gt;]. The trial was still on hold in November 2005  [&lt;ulink linkID="633246" linkType="Reference"&gt;633246&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the first quarter of 2001, Aventis began a 12-week, double-blind, randomized, placebo-controlled phase IIa trial of pralnacasan involving patients with RA. The trial was expected to enroll 250 adult patients with active RA who were to receive either pralnacasan or placebo [&lt;ulink linkID="407005" linkType="reference"&gt;407005&lt;/ulink&gt;]. Enrollment was complete as of October 2001 and at this time the trial was expected to be complete in the first half of 2002 [&lt;ulink linkID="426795" linkType="reference"&gt;426795&lt;/ulink&gt;], [&lt;ulink linkID="435164" linkType="reference"&gt;435164&lt;/ulink&gt;], [&lt;ulink linkID="436431" linkType="reference"&gt;436431&lt;/ulink&gt;]; in February 2002, data analysis was anticipated in the second quarter of 2002 [&lt;ulink linkID="438940" linkType="reference"&gt;438940&lt;/ulink&gt;]. Data from the trial were presented in April 2002. The data demonstrated that patients receiving pralnacasan had a strong trend toward a dose-dependent improvement in signs and symptoms of disease, as measured by ACR20 response rates after 12 weeks. Analyses of patient subgroups not receiving concomitant DMARDs, methotrexate or corticosteroids showed similar strong trends indicative of pralnacasan's anti-inflammatory effect. Patients receiving the high dose of pralnacasan in the intention-to-treat population exhibited ACR20 response rates greater than 40%. Pralnacasan demonstrated good tolerability alone and in combination with other RA therapies when administered for up to 24 weeks [&lt;ulink linkID="449230" linkType="reference"&gt;449230&lt;/ulink&gt;], [&lt;ulink linkID="455054" linkType="reference"&gt;455054&lt;/ulink&gt;]. Similar data were presented at the American College of Rheumatology (ACR) 66th Annual Scientific Meeting in New Orleans, LA. In post-hoc subset analyses, patients receiving stable concomitant methotrexate (MTX) treatment for more than 6 months or those not receiving concomitant MTX treatment exhibited significant, dose-dependent improvement in ACR20 response rates with pralnacasan treatment. Treatment with pralnacasan enabled patients to reduce their concomitant corticosteroid therapy [&lt;ulink linkID="468335" linkType="reference"&gt;468335&lt;/ulink&gt;], [&lt;ulink linkID="470328" linkType="reference"&gt;470328&lt;/ulink&gt;]. Data were also presented at the Advances in Anti-Arthritic Agents - 3rd SMi meeting in London, UK, in April 2002. A significant reduction in inflammatory serum markers, such as C-reactive protein and serum amylin A was observed  [&lt;ulink linkID="450049" linkType="reference"&gt;450049&lt;/ulink&gt;], [&lt;ulink linkID="460724" linkType="reference"&gt;460724&lt;/ulink&gt;]. Similar data were reported at the 12th Biennial International Inflammation Research Association meeting in Bolton Landing, NY, in October 2004 [&lt;ulink linkID="563401" linkType="Reference"&gt;563401&lt;/ulink&gt;], [&lt;ulink linkID="563694" linkType="Reference"&gt;563694&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 1999, Vertex initiated a 28 day phase IIa trial of pralnacasan in patients with RA [&lt;ulink linkID="339915" linkType="reference"&gt;339915&lt;/ulink&gt;]; the trial was completed in 2000 [&lt;ulink linkID="484915" linkType="reference"&gt;484915&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 1998, Vertex started a phase I trial of pralnacasan which was to involve 50 healthy volunteers and was to assess the pharmacokinetics and tolerability of the compound in a range of single doses [&lt;ulink linkID="302985" linkType="reference"&gt;302985&lt;/ulink&gt;]; the trial had been completed by 1999. Data presented demonstrated that pralnacasan was well tolerated in humans in a range of single doses and has excellent safety and bioavailability [&lt;ulink linkID="409257" linkType="reference"&gt;409257&lt;/ulink&gt;], [&lt;ulink linkID="484915" linkType="reference"&gt;484915&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OSTEOARTHRITIS&lt;/subtitle&gt;By January 2003, a phase II proof-of-concept study in OA had been initiated by Aventis. The trial was to evaluate 400 patients treated with pralnacasan or placebo for 12 weeks and was to evaluate the safety and efficacy of the compound [&lt;ulink linkID="475719" linkType="reference"&gt;475719&lt;/ulink&gt;], [&lt;ulink linkID="475831" linkType="Reference"&gt;475831&lt;/ulink&gt;], [&lt;ulink linkID="478012" linkType="Reference"&gt;478012&lt;/ulink&gt;], [&lt;ulink linkID="488216" linkType="Reference"&gt;488216&lt;/ulink&gt;]. In April 2003, Vertex reported that patient enrollment in this study had been completed [&lt;ulink linkID="487210" linkType="reference"&gt;487210&lt;/ulink&gt;], [&lt;ulink linkID="495755" linkType="reference"&gt;495755&lt;/ulink&gt;]. In September 2003, results from this trial were expected in late 2003 [&lt;ulink linkID="509199" linkType="reference"&gt;509199&lt;/ulink&gt;]. In January 2004, this dose-escalating trial of 500 patients was completed; pralnacasan was well-tolerated  and there was improvement in the Western Ontario and McMasters Universities scale of OA symptoms (WOMAC) score in all treatment groups, although this was  not significant.  Statistically significant changes were observed in certain biomarkers  [&lt;ulink linkID="633246" linkType="Reference"&gt;633246&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; By October 2001, pralnacasan was in phase II trials for OA [&lt;ulink linkID="427421" linkType="reference"&gt;427421&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PSORIASIS&lt;/subtitle&gt;By September 2003, a proof-of-concept clinical study in psoriasis was in preparation [&lt;ulink linkID="507748" linkType="Reference"&gt;507748&lt;/ulink&gt;], [&lt;ulink linkID="509199" linkType="Reference"&gt;509199&lt;/ulink&gt;]; this was underway by February 2004 [&lt;ulink linkID="523891" linkType="Reference"&gt;523891&lt;/ulink&gt;], [&lt;ulink linkID="524359" linkType="Reference"&gt;524359&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In July 2002, preclinical data on pralnacasan were presented at the Drug Discovery Technology 2002 meeting in Boston, MA. In Type II collagen-induced arthritic DBA/1 mice the drug reduced disease severity by up to 70% and reduced lesion incidence in bone and cartilage. No dose limiting toxicity was observed for up to 6 months in rats and dogs [&lt;ulink linkID="460724" linkType="reference"&gt;460724&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2002, preclinical data on pralnacasan were presented at the Digestive Disease Week meeting in San Francisco, CA. In the murine DSS-induced colitis model, 100 mg/kg pralnacasan ip qd significantly reduced the disease activity score and expression of TNFalpha, IL-18, IFNgamma and IP-10 in colonic tissue. These data suggested that pralnacasan may be beneficial in Crohn's disease [&lt;ulink linkID="451847" linkType="reference"&gt;451847&lt;/ulink&gt;], [&lt;ulink linkID="476528" linkType="reference"&gt;476528&lt;/ulink&gt;]. Similar data were presented at the DDW meeting in New Orleans, LA in May 2004 where pralnascan was shown to protect mice against Th1- and Th2-mediated colitis. In a murine models of TNBS-induced colitis, pralnascan produced a 50% reduction in mortality and a significant reduction of inflammation and weight loss. Similar results were found in oxasolone-induced colitis [&lt;ulink linkID="538577" linkType="reference"&gt;538577&lt;/ulink&gt;], [&lt;ulink linkID="540043" linkType="reference"&gt;540043&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 1994, Vertex reported that it had solved the 3-dimensional structure of the ICE enzyme using X-ray crystallography [&lt;ulink linkID="170250" linkType="reference"&gt;170250&lt;/ulink&gt;]. The creation of the ICE gene knockout mouse in 1995 provided a strong biological foundation for ICE inhibition as a therapeutic strategy, and pralnacasan was selected as a lead development candidate in 1997 [&lt;ulink linkID="302985" linkType="reference"&gt;302985&lt;/ulink&gt;]. Pralnacasan is delivered as a prodrug, the active metabolite of which is VE-18858, with a bioavailability of 43% [&lt;ulink linkID="306496" linkType="reference"&gt;306496&lt;/ulink&gt;]. It is orally active in a number of animal models of human inflammatory disease, including one for chronic arthritis [&lt;ulink linkID="257441" linkType="reference"&gt;257441&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 1993, Vertex signed a strategic alliance with &lt;ulink linkID="26135" linkType="Company"&gt;Roussel Uclaf&lt;/ulink&gt; (now &lt;ulink linkID="1009547" linkType="Company"&gt;sanofi-aventis&lt;/ulink&gt;). Under the terms of the agreement, Roussel retained the right to select one or more compounds for development and to license such compound or compounds from Vertex [&lt;ulink linkID="273064" linkType="reference"&gt;273064&lt;/ulink&gt;], [&lt;ulink linkID="257441" linkType="reference"&gt;257441&lt;/ulink&gt;]. This development was continued under &lt;ulink linkID="27779" linkType="Company"&gt;Aventis Pharma&lt;/ulink&gt; (formerly &lt;ulink linkID="25223" linkType="Company"&gt;Hoechst Marion Roussel&lt;/ulink&gt; (HMR)). In September 1999, HMR and Vertex signed an expanded agreement covering pralnacasan to develop novel anti-inflammatory compounds [&lt;ulink linkID="338587" linkType="reference"&gt;338587&lt;/ulink&gt;]. However, in February 2005, sanofi-aventis  revealed that it would terminate this deal, upon which, worldwide rights to pralnacasan would revert to Vertex [&lt;ulink linkID="584113" linkType="Reference"&gt;584113&lt;/ulink&gt;]. The drug did not appear on sanofi-aventis' first pipeline in 2004, so it has been presumed that sanofi-aventis was no longer developing it [&lt;ulink linkID="587512" linkType="Reference"&gt;587512&lt;/ulink&gt;]. This was confirmed by Vertex in April 2005 [&lt;ulink linkID="597722" linkType="Reference"&gt;597722&lt;/ulink&gt;] and by sanofi-aventis in August 2005 [&lt;ulink linkID="620356" linkType="Reference"&gt;620356&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 1997, Vertex purchased a portfolio of ten patent application families claiming ICE inhibitors from &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi SA&lt;/ulink&gt;. The applications in the portfolio had been filed in the US and worldwide [&lt;ulink linkID="257441" linkType="reference"&gt;257441&lt;/ulink&gt;]. WO-09722619 and WO-09946248 cover diazepane inhibitors of ICE and diazepane derivatives as inhibitors of ICE and are related to this record.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;There are two evaluations of this drug.&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;Britta Siegmund &amp;amp; Martin Zeitz, Universitatsklinikum Benjamin Franklin, Freie Universitat Berlin, Berlin, Germany&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Submission Date: 28 November 2002&lt;/subtitle&gt;Publication Date: 15 January 2003&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="9271"&gt;Pralnacasan&lt;/ulink&gt; represents a new compound class of protease inhibitors and inhibits the interleukin (IL)-1beta converting enzyme (ICE), also known as caspase-1. Caspase is an acronym for 'cysteine aspartic acid-specific protease'. The ICE gene codes for a 45-kDa inactive precursor protein that is constitutively expressed in many cell types. As with most caspases, the precursor of ICE requires two internal cleavages before becoming enzymatically active as a heterodimer comprised of 10- and 20-kDa chains [&lt;ulink linkType="reference" linkID="472044"&gt;472044&lt;/ulink&gt;]. ICE itself contributes to autoprocessing of the ICE precursor by undergoing oligomerization with itself or other members of the caspase family, such as caspase-3 [&lt;ulink linkType="reference" linkID="244862"&gt;244862&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="472045"&gt;472045&lt;/ulink&gt;]. Unlike other caspases, ICE is not dominantly involved in apoptosis induction, the major role of most caspases. In contrast, it is required for the activation of the two pro-inflammatory cytokines IL-1beta and IL-18 [&lt;ulink linkType="reference" linkID="472046"&gt;472046&lt;/ulink&gt;]. Both are synthesized as inactive precursors and await activation by ICE after cell stimulation. The cleavage of the inactive precursor proteins pro-IL-1beta and pro-IL-18 is subsequently followed by secretion through an as yet unknown mechanism. Therefore, inhibition of ICE results in a parallel suppression of active IL-1beta as well as IL-18, both of which are known to be involved in a plethora of pathophysiological pathways. &lt;/para&gt;&lt;para&gt;The role of ICE has been characterized in several models of in vivo inflammation. The creation of the ICE gene knockout (KO) mouse in 1995 provided evidence that ICE inhibition was a potential therapeutic strategy [&lt;ulink linkType="reference" linkID="302985"&gt;302985&lt;/ulink&gt;]. ICE-deficient mice are resistant to lethal endotoxemia, but this is due to a failure to process pro-IL-18 and induce interferon (IFN)-gamma rather than the inhibition of IL-1beta [&lt;ulink linkType="reference" linkID="472047"&gt;472047&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="472048"&gt;472048&lt;/ulink&gt;]. Direct and indirect evidence also exists suggesting that ICE might be of significance in inflammatory bowel disease (IBD). An early study of ICE and IBD by McAlindon and colleagues led to the observation that exposure of normal colonic macrophages to lipopolysaccharide (LPS) induced production of precursor IL-1beta, because the cells failed to activate ICE [&lt;ulink linkType="reference" linkID="288347"&gt;288347&lt;/ulink&gt;]. In contrast, colonic macrophages from patients with IBD were able to activate ICE and hence release mature IL-1beta in a manner similar to circulating monocytes. In addition, consistent with an increased T-helper cell type 1 response in Crohn's disease, several groups independently demonstrated a significant upregulation of IL-18 in the inflamed lesion of the intestine, mostly localized to epithelial cells and macrophages [&lt;ulink linkType="reference" linkID="472049"&gt;472049&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="472051"&gt;472051&lt;/ulink&gt;]. While increased expression of IL-18 provides the first evidence for a possible role in disease, in order to prove that IL-18 participates in the inflammatory process of intestinal inflammation it has to be demonstrated that blockade of IL-18 results in amelioration of disease severity. Interestingly, ICE KO mice are protected against acute and chronic dextran sulfate sodium (DSS)-induced colitis [&lt;ulink linkType="reference" linkID="472052"&gt;472052&lt;/ulink&gt;]. In particular, during chronic administration of DSS over 4 weeks, ICE KO mice presented almost complete absence of colitis. This amelioration was accompanied by reduced cell activation in the draining mesenteric lymph nodes and significant reduction of the pro-inflammatory cytokines IL-18, IFNgamma and IL-1beta in the colon. This appears to be due to neutralization of IL-18, as blockade of IL-1beta alone resulted only in a mild decrease in disease severity while neutralization of IL-18 led to a significant amelioration of DSS-induced colitis [&lt;ulink linkType="reference" linkID="472054"&gt;472054&lt;/ulink&gt;]. The beneficial effect of IL-18 neutralization was confirmed in different experimental models of colitis using different anti-IL-18 strategies [&lt;ulink linkType="reference" linkID="472058"&gt;472058&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="472060"&gt;472060&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="472061"&gt;472061&lt;/ulink&gt;]. Furthermore, in different models of acute pancreatitis, inhibition of ICE by the administration of an irreversible ICE inhibitor was protective [&lt;ulink linkType="reference" linkID="260301"&gt;260301&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="472063"&gt;472063&lt;/ulink&gt;]. In melanoma studies, the number of hepatic metastases after intrasplenically injected mouse B16 melanoma cells was 84 to 95% lower in ICE KO than wild-type mice [&lt;ulink linkType="reference" linkID="472064"&gt;472064&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;In July 1994, Vertex reported that it had identified the 3-dimensional structure of the ICE enzyme using X-ray crystallography [&lt;ulink linkType="reference" linkID="472045"&gt;472045&lt;/ulink&gt;]. A structure-based design program used crystallographic structural data to model the interaction between ICE and the acetylated tetrapeptide ICE inhibitor AcYVAD-CHO and to guide selection of peptidomimetic scaffolds to establish similar interactions. The pyridazinodiazepine scaffold provided excellent peptide-backbone fit in silico, and appropriate substitutions analogous to the P4 tyrosine of AcYVAD-CHO afforded highly potent and selective ICE inhibitors in vitro [&lt;ulink linkType="reference" linkID="468965"&gt;468965&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The oral bioavailability of AcYVAD-CHO is poor, but much improved prodrugs, where this functional group is hidden in a hydrolyzable ring structure, demonstrate excellent bioavailability [&lt;ulink linkType="reference" linkID="468965"&gt;468965&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="9271"&gt;Pralnacasan&lt;/ulink&gt; emerged from this program in 1997 and was the first selective ICE inhibitor to enter clinical development; it is delivered as a prodrug with a bioavailability of 43% [&lt;ulink linkType="reference" linkID="306496"&gt;306496&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;Inhibition of ICE and other caspases was assayed by fluorometric tracking of the rate of hydrolysis of an appropriate substrate labeled with either 4-nitroanaline or aminomethyl coumarin [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;]. IC50 values for RU/VRT, the active metabolite of &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt;, against other human serine proteases (elastase, chymotrypsin and thrombin) or cysteine proteases, including cathepsins L and B, were determined to be &amp;gt; 100 mM. The results from these studies indicate that RU/VT is a highly potent inhibitor of both ICE and group 1 caspases and is selective for these against group 2 and group 3 caspases [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Cellular activity was determined using human peripheral blood mononuclear cells from healthy volunteers. Cells were stimulated with either LPS or Staphylococcus aureus Cowan (SAC) and the inhibition of IL-1beta, IL-18, IFNgamma and IL-1alpha by RU/VRT were measured.  IC50 values for IL-1beta (LPS = 0.85 microM; SAC = 3.7 microM), IL-18 (SAC = 6.6 microM); IFNgamma (SAC = 12.3 microM), IL-1alpha (LPS = 34 microM) were determined in this in vitro system [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In two in vivo models the dose-dependent inhibition of IL-1beta after oral administration of &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; was demonstrated. The LPS challenge was conducted in male CD-1 mice (8 to 9 weeks of age). &lt;ulink linkType="Drug" linkID="9271"&gt;Pralnacasan&lt;/ulink&gt; (10 to 100 mg/kg) was administered by gavage 1 h after the LPS injection and resulted in a 35 to 80% inhibition of the LPS-induced rise in plasma IL-1beta production. In the second model, the carrageenan challenge, peritoneal inflammation was induced in male CD-1 mice by carrageenan injection (10 mg in 0.5 ml saline); &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; (1 to 100 mg/kg) was administered 1 h following carrageenan challenge. Drug administration led to a 30 to 75% inhibition of carrageenan-induced rise in IL-1beta in peritoneal exudate [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a second study, &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; was administered at 100 mg/kg qd intraperitoneally to mice for 10 days during acute DSS-induced colitis, resulting in significant reduction of the disease activity score [&lt;ulink linkType="reference" linkID="451847"&gt;451847&lt;/ulink&gt;]. Disease amelioration was accompanied by decreased expression of the pro-inflammatory mediators TNFalpha, IFNgamma and IP-10 in colonic tissue. In addition, histological evaluation of the colon at the end of the experiment revealed significantly less inflammation in &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt;-treated compared to vehicle-treated mice [&lt;ulink linkType="reference" linkID="451847"&gt;451847&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="9271"&gt;Pralnacasan&lt;/ulink&gt; inhibited type II collagen-induced arthritis in DBA/1 mice at 50 mg/kg bid and demonstrated efficacy in both the therapeutic and prophylactic models [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;]. In the prophylactic protocol, &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; (10 to 100 mg/kg po bid) was administered at the time of booster collagen injection and a dose-dependent delay in onset of symptoms was demonstrated [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;]. In the therapeutic protocol, mice were treated after booster immunization until they reached an inflammation score of 2 (erythema and focal swelling of the wrist) on each front paw (total score of 4) and were then randomly assigned to treatment group. Animals treated with &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; experienced a progressive reduction in paw swelling during the first 10 days of treatment and relatively stable disease thereafter [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;]. The drug reduced disease severity by up to 70%. Prophylactic treatment with &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; concomitantly reduced the incidence of cartilage (~ 56%) and bone (~ 81%) lesions [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;Studies in rats indicate that oral bioavailability is increased ~ 10-fold from ~ 4% for RU/VRT to 40 to 60% for &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="9271"&gt;Pralnacasan&lt;/ulink&gt; (50 mg/kg) administered to rats resulted in a Tmax of 0.56 h, a Cmax of 7.3 microg/ml and an AUC0-8 h of 15.7 microg.h/ml [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;]. The phase I clinical programs confirmed that &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; is well absorbed from oral formulations and achieves plasma levels sufficient to inhibit the production of IL-1beta in an ex vivo assay [&lt;ulink linkType="reference" linkID="450049"&gt;450049&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="460724"&gt;460724&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No dose-limiting toxicity was observed for up to 6 months in rats or dogs [&lt;ulink linkType="reference" linkID="460724"&gt;460724&lt;/ulink&gt;]. Toxicity has not been observed in clinical trials to date [&lt;ulink linkType="reference" linkID="468335"&gt;468335&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;Phase I studies demonstrated that &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; was well tolerated [&lt;ulink linkType="reference" linkID="450049"&gt;450049&lt;/ulink&gt;] and displayed good oral bioavailability and safety [&lt;ulink linkType="reference" linkID="409257"&gt;409257&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II &lt;/subtitle&gt;Data from a 285-patient trial, conducted by Aventis at 31 centers in seven European countries, were released in October 2002 at the American College of Rheumatology (ACR) 6th Annual Scientific Meeting [&lt;ulink linkType="reference" linkID="468335"&gt;468335&lt;/ulink&gt;]. These data demonstrated that &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; was well tolerated and had positive anti-inflammatory effects in patients with RA. The study was a 12-week, double-blind, randomized, placebo-controlled trial in which patients were to receive &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; (100 or 400 mg tid) or placebo (tid) with the option of a 12-week extension of treatment. A dose-dependent trend toward improvement in signs and symptoms of disease, as measured by ACR20 response rates after 12 weeks, was observed in patients who received the drug. &lt;ulink linkType="Drug" linkID="9271"&gt;Pralnacasan&lt;/ulink&gt; (1200 mg/day) administered to patients in the intention-to-treat population led to ACR20 response rates of 44% compared to the placebo group response rate of 32.7%. Patients receiving the 1200 mg/day dose had statistically significant reductions in the inflammatory biomarkers C-reactive protein, erythrocyte sedimentation rate and serum amyloid A. &lt;ulink linkType="Drug" linkID="9271"&gt;Pralnacasan&lt;/ulink&gt; treatment enabled patients to reduce their additional corticosteroid therapy [&lt;ulink linkType="reference" linkID="449230"&gt;449230&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="460724"&gt;460724&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="468335"&gt;468335&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="470328"&gt;470328&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Since October 2001, &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; has been in phase II clinical trials for osteoarthritis. No data have been released from these studies [&lt;ulink linkType="reference" linkID="427421"&gt;427421&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;Adverse events including mild-to-moderate diarrhea and nausea have been reported. These were unrelated to dose, however, and were only seen in &amp;lt; 5% of the study population [&lt;ulink linkType="reference" linkID="468335"&gt;468335&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="470328"&gt;470328&lt;/ulink&gt;]. The maximum dose administered during clinical trials was 1200 mg/day [&lt;ulink linkType="reference" linkID="468335"&gt;468335&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent Commentary&lt;/subtitle&gt;The compounds disclosed in US patent US-00575641 are inhibitors of ICE. These inhibitors are characterized by specific structural and physicochemical features, making them particularly well suited for inhibiting ICE activity. Over 800 compounds are disclosed as representative. The specificied compound, 3S-[(4S;7S)-7-(isoquinolin-1-ylcarbonylamino)-6,10-dioxoperhydropyridazinol[1,2-a][1,2]diazepin-4-ylcarbonylamino]-4-oxobutanoic acid, is one of 271 compounds specifically claimed. These compounds were characterized by optical rotation, infrared, elemental analysis and 1H-NMR data [&lt;ulink linkType="reference" linkID="257441"&gt;257441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="9271"&gt;Pralnacasan&lt;/ulink&gt; represents a new compound class of protease inhibitors. It has good oral bioavailability and an excellent toxicity profile with no significant side effects [&lt;ulink linkType="reference" linkID="468335"&gt;468335&lt;/ulink&gt;]. Animal models indicate that the drug has therapeutic efficacy in collagen-induced arthritis [&lt;ulink linkType="reference" linkID="474260"&gt;474260&lt;/ulink&gt;], and phase II clinical trials confirm these data. Further studies are required, however, in order to determine the subgroup of patients who would benefit most from &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt;. In addition, data suggest that &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; may have potential in other diseases, for instance, a study in patients with osteoarthritis is being conducted [&lt;ulink linkType="reference" linkID="427421"&gt;427421&lt;/ulink&gt;]. Another chronic inflammatory disease for which ICE inhibition may be beneficial is colitis [&lt;ulink linkType="reference" linkID="451847"&gt;451847&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="468962"&gt;468962&lt;/ulink&gt;]. Clinical trials will, however, have to prove the efficacy of &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; in patients with IBD. In conclusion, compared to current strategies to suppress specific cytokines, &lt;ulink linkType="Drug" linkID="9271"&gt;pralnacasan&lt;/ulink&gt; is a promising, orally bioavailable drug.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Tomasz M Sobow, Medical University of Lodz, Poland&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Publication date: 20 July 1998&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;VX-740 is an interleukin 1-beta (IL-1beta) converting enzyme (ICE) inhibitor proposed for the treatment of several inflammatory diseases, including Alzheimer's disease (AD) [&lt;ulink linkType="reference" linkID="170247"&gt;170247&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="188293"&gt;188293&lt;/ulink&gt;]. The rationale of using this ICE inhibitor (which is now in preclinical development) in AD treatment is that the neuronal loss is a prominent feature of the disease. Neuronal death is mainly mediated by apoptosis, and ICE, belonging to caspase family, may interfere with this process. Apoptotic cell death occurs in two phases. Firstly, neurones undergo a commitment to death, which is triggered by various factors. It has been notably shown to be triggered by amyloid-beta (A-beta), the main component of amyloid plaques in AD brains, and also by mutated amyloid precursor protein (APP) [&lt;ulink linkType="reference" linkID="300402"&gt;300402&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="300404"&gt;300404&lt;/ulink&gt;]. The second stage is an execution in which caspases play an important role [&lt;ulink linkType="reference" linkID="300403"&gt;300403&lt;/ulink&gt;]. Inhibiting the executory phase of apoptotic cell death diminishes neuronal cell death and as a result slows the progression of the disease. However, since ICE is normally expressed in neurons and is implicated in many physiological processes, its use in the treatment of AD, although attractive, needs to be preceded by very careful investigations.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;VX-740 is an ICE inhibitor that is orally-active in a number of animal models of human inflammatory diseases [&lt;ulink linkType="reference" linkID="257441"&gt;257441&lt;/ulink&gt;]. The compound was synthesized by so called reverse technology. First the three-dimensional structure of ICE was solved using X-ray crystallography [&lt;ulink linkType="reference" linkID="170250"&gt;170250&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="173167"&gt;173167&lt;/ulink&gt;]. Then some additional structural and kinetic studies have been done [&lt;ulink linkType="reference" linkID="177138"&gt;177138&lt;/ulink&gt;]. Finally a group of proposed compounds to block an activity of ICE have been synthesized, rooting their structure from the previous studies on ICE [&lt;ulink linkType="reference" linkID="237775"&gt;237775&lt;/ulink&gt;]. Kinetic constants for several reversible inhibitors and irreversible inactivators, which have been used to implicate one or more caspases, were also reported [&lt;ulink linkType="reference" linkID="244861"&gt;244861&lt;/ulink&gt;]. It is important to note that potentially many other compounds can be synthesized using the same fruitful approach [&lt;ulink linkType="reference" linkID="257441"&gt;257441&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="265872"&gt;265872&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;To date, VX-740 has not been investigated in any animal models of AD. However, some data is currently available in rodent models of sepsis, acute inflammation and chronic arthritis, where the compound is active after both intraperitoneal and subcutaneous administration. Furthermore, the ICE inhibition is still detected in bioactive levels in the plasma 7 hours after administration [&lt;ulink linkType="reference" linkID="215806"&gt;215806&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion:&lt;/subtitle&gt;Existing treatments for AD are by and large symptomatic only. None of the currently used drugs have been shown to change the course of the disease. Interfering with neuronal cell death seems to be a potentially interesting approach. A wealth of research conducted in this field has shown that an apoptotic pathway is the most prominent mechanism of cell death, which constitutes an active and disease-specific therapeutic target. Notably, A-beta induces apoptosis both in vitro [&lt;ulink linkType="reference" linkID="300402"&gt;300402&lt;/ulink&gt;],[&lt;ulink linkType="reference" linkID="300404"&gt;300404&lt;/ulink&gt;] and in vivo [&lt;ulink linkType="reference" linkID="225800"&gt;225800&lt;/ulink&gt;]. Additionally, the presenilins, other proteins implicated in the pathogenesis of AD, are substrates for caspases [&lt;ulink linkType="reference" linkID="300405"&gt;300405&lt;/ulink&gt;], whilst the mutations in one of the presenilin genes (PS-2) is proposed to activate an apoptotic pathway in a similar way to the ALG-3 gene in mice [&lt;ulink linkType="reference" linkID="210434"&gt;210434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Interfering with apoptosis may then interact with some major pathways of disease development, and thus VX-740 may be a promising novel compound for this purpose.&lt;/para&gt;&lt;para&gt;However, the use of VX-740 in humans is a long way off. Firstly, it must be shown that the compound interacts with major proteins involved in the pathogenesis of AD. Several cell models may be employed to reveal a possible interaction with APP, presenilins and proteoglycans, to name but a few. Secondly, it would be necessary to employ transgenic models of AD, to study the effects of the compound on AD-like neuropathology development in mice. Finally, of critical importance, it has to shown that the compound posses a disease-specific mode of action. One should remember that ICE is widely expressed in numerous other human cells and tissues than those affected in AD. The adverse non-CNS side-effects observed with &lt;ulink linkType="Drug" linkID="4509"&gt;tacrine&lt;/ulink&gt;, an acetylcholinesterase inhibitor, highlight the need for brain specificity.&lt;/para&gt;&lt;para&gt;Bearing in mind all the above limitations, one can, however, evaluate the prospect of the use of VX-740 in the treatment of AD as promising. Other diseases could also be recommended for consideration as potential targets for its use, eg, Huntington's disease and other triplet repeat disorders and prion-associated diseases.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1069">Metastasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-15T00:00:00.000Z</StatusDate><Source id="401955" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="97">Diabetes mellitus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-15T00:00:00.000Z</StatusDate><Source id="401955" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-15T00:00:00.000Z</StatusDate><Source id="401955" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-04-26T00:00:00.000Z</StatusDate><Source id="597722" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-04-26T00:00:00.000Z</StatusDate><Source id="597722" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-04-26T00:00:00.000Z</StatusDate><Source id="597722" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-03-15T00:00:00.000Z</StatusDate><Source id="401955" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-04-26T00:00:00.000Z</StatusDate><Source id="597722" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-08-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-07-10T00:00:00.000Z</StatusDate><Source id="496567" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-01-31T00:00:00.000Z</StatusDate><Source id="231862" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="97">Diabetes mellitus</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-01-31T00:00:00.000Z</StatusDate><Source id="231862" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1069">Metastasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-01-31T00:00:00.000Z</StatusDate><Source id="231862" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-09-01T00:00:00.000Z</StatusDate><Source id="188293" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-05-21T00:00:00.000Z</StatusDate><Source id="409257" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-12-23T00:00:00.000Z</StatusDate><Source id="351501" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-10-31T00:00:00.000Z</StatusDate><Source id="427421" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-02-05T00:00:00.000Z</StatusDate><Source id="523891" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-03-01T00:00:00.000Z</StatusDate><Source id="587512" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-03-01T00:00:00.000Z</StatusDate><Source id="587512" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-03-01T00:00:00.000Z</StatusDate><Source id="587512" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-03-01T00:00:00.000Z</StatusDate><Source id="587512" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-07-10T00:00:00.000Z</StatusDate><Source id="496567" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-05-21T00:00:00.000Z</StatusDate><Source id="409257" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-02-05T00:00:00.000Z</StatusDate><Source id="524359" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-09-01T00:00:00.000Z</StatusDate><Source id="188293" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-09-01T00:00:00.000Z</StatusDate><Source id="188293" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-09-01T00:00:00.000Z</StatusDate><Source id="188293" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2004-02-05T00:00:00.000Z</StatusDate><Source id="524359" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-05-17T00:00:00.000Z</StatusDate><Source id="170247" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-10-30T00:00:00.000Z</StatusDate><Source id="427421" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20739">Vertex Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-09-16T00:00:00.000Z</StatusDate><Source id="339915" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-10-30T00:00:00.000Z</StatusDate><Source id="302985" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-09-17T00:00:00.000Z</StatusDate><Source id="339915" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00971"><Name>ICE</Name><SwissprotNumbers><Swissprot>O02002</Swissprot><Swissprot>P29452</Swissprot><Swissprot>P29466</Swissprot><Swissprot>P43527</Swissprot><Swissprot>P89116</Swissprot><Swissprot>Q9MZV6</Swissprot><Swissprot>Q9MZV7</Swissprot><Swissprot>Q9N2I1</Swissprot><Swissprot>Q9TV13</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20739">Vertex Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCO[C@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN3N2C(=O)[C@H](CCC3=O)NC(=O)c4c5ccccc5ccn4</Smiles></StructureSmiles><Deals><Deal id="121186" title="Vertex and HMR to collaborate on compound development, including pralnacasan                    "></Deal><Deal id="121482" title="Aventis to develop Vertex Pharmaceuticals' pralnacasan"></Deal></Deals><PatentFamilies><PatentFamily id="1060291" number="WO-00042061" title="Method for preparing bicyclic compounds and use of said method for preparing an interleukin-1$g(B) conversion enzyme (ICE) inhibitor"></PatentFamily><PatentFamily id="1088547" number="WO-09952935" title="Crystalline forms of 1S-[1alpha(2S*,3R*),9alpha]-6,10-dioxo-N-(2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9-[[(1-isoquinolyl)carbonyl]-amino]octahydro-6H-piridazino[1,2-a][1,2]diazepin-1-carboxamide."></PatentFamily><PatentFamily id="1174710" number="WO-2005115362" title="Treating seizures using ICE inhibitors"></PatentFamily><PatentFamily id="1459223" number="WO-09722619" title="Inhibitors of interleukin-1beta converting enzyme."></PatentFamily><PatentFamily id="1680680" number="WO-09955724" title="Novel Octahydro-6,10-Dioxo-6h-Pyridazino/1,2-A/ /1,2/Diazepin-1-Carboxylic Acid Derivatives, Preparation Method And Use For Preparing Therapeutically Active Compounds"></PatentFamily><PatentFamily id="1680827" number="WO-00183458" title="Asymmetric synthesis of piperazic acid and derivatives thereof"></PatentFamily><PatentFamily id="1805508" number="WO-00181330" title="Process and intermediates for making substituted aspartic acid acetals"></PatentFamily><PatentFamily id="1807674" number="WO-2005053665" title="Treating infectious diseases using ICE inhibitors"></PatentFamily><PatentFamily id="201398" number="WO-00010979" title="Process For Preparing Piperazic Acid And Its Conversion To N-Acylated Bicyclic Rings Containing N,N-Linkages Useful As Intermediates For Caspase Inhibitors"></PatentFamily><PatentFamily id="2177708" number="WO-2005047906" title="Methods for monitoring IL-18"></PatentFamily><PatentFamily id="2344113" number="WO-00119390" title="Combination treatment with IL-1ra and diaryl sulphonyl urea compounds"></PatentFamily><PatentFamily id="2825054" number="WO-2014178715" title="Personalised medicine"></PatentFamily><PatentFamily id="3595033" number="WO-2017059427" title="Methods for monitoring and determining the prognosis of strokes, peripheral vascular disease, shock, and sickle cell disease and its complications"></PatentFamily><PatentFamily id="549418" number="WO-2005090334" title="Processes and intermediates"></PatentFamily><PatentFamily id="764322" number="WO-09930852" title="Method Of Molding High Expansion Pipe, And The High Expansion Pipe"></PatentFamily><PatentFamily id="865272" number="WO-2005117846" title="Treatment of diseases using ice inhibitors"></PatentFamily><PatentFamily id="951562" number="WO-2007042160" title="Retard formulation for pralnacasan"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Radboud University" id="1031299"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Taisho Pharmaceutical Co Ltd" id="20289"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vertex Pharmaceuticals Inc" id="20739"></CompanyLink><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Children's National Medical Center" id="21053"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>